Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
21 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Niagen Bioscience, Inc.’s names, not what it holds today.
Patents granted
21
21 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against none in 2024 and 1 in 2023
Applications published
28
2 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'05'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry7
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ChromaDex Inc. a former name
US, as the owner printed on each patent. 4 more under the same name are not counted (printed in GB)
24 publishedChromaDex Inc. a former name
named as the applicant on its applications, in US
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 2, 2025 | 12,485,134 | Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations | Pharmaceuticals | ChromaDex Inc. |
| Oct 7, 2025 | 12,433,908 | Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development | Pharmaceuticals | ChromaDex Inc. |
| Jan 14, 2025 | 12,195,494 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Organic fine chemistry | ChromaDex Inc. |
| Sep 5, 2023 | 11,746,123 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Organic fine chemistry | ChromaDex Inc. |
| Dec 13, 2022 | 11,524,022 | Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development | Pharmaceuticals | ChromaDex Inc. |
| May 31, 2022 | 11,345,720 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Organic fine chemistry | ChromaDex Inc. |
| Mar 15, 2022 | 11,274,117 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Organic fine chemistry | ChromaDex Inc. |
| Feb 8, 2022 | 11,242,364 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | Organic fine chemistry | ChromaDex Inc. |
| Jan 4, 2022 | 11,214,589 | Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereof | Organic fine chemistry | ChromaDex Inc. |
| Jun 15, 2021 | 11,033,568 | Nicotinamide riboside compositions for topical use in treating skin conditions | Pharmaceuticals | ChromaDex Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 14, 2025 | 2025/0255896 | NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF | Pharmaceuticals | ChromaDex Inc. |
| May 22, 2025 | 2025/0163093 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | Organic fine chemistry | ChromaDex Inc. |
| Dec 19, 2024 | 2024/0415863 | NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF | Pharmaceuticals | ChromaDex Inc. |
| Dec 7, 2023 | 2023/0391815 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | Organic fine chemistry | ChromaDex Inc. · patent 12,195,494 granted from it |
| Sep 21, 2023 | 2023/0295211 | METHODS OF PRODUCING CRYSTALLINE BETA NICOTINAMIDE RIBOSIDE TRIACETATE CHLORIDE | Organic fine chemistry | ChromaDex Inc. |
| Jun 29, 2023 | 2023/0201233 | USE OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, AND NICOTINAMIDE MONONUCLEOTIDE, REDUCED NICOTINYL COMPOUNDS, AND NICOTINOYL COMPOUND DERIVATIVES IN INFANT FORMULA FOR HEALTHY DEVELOPMENT | Pharmaceuticals | ChromaDex Inc. · patent 12,433,908 granted from it |
| Aug 4, 2022 | 2022/0241305 | ETHYL CELLULOSE BASED COATINGS FOR MICROENCAPSULATION OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS, AND NICOTINYL RIBOSIDE COMPOUND DERIVATIVES | Pharmaceuticals | ChromaDex Inc. |
| Apr 7, 2022 | 2022/0106350 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | Organic fine chemistry | ChromaDex Inc. · patent 11,345,720 granted from it |
| Nov 25, 2021 | 2021/0363168 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | Organic fine chemistry | ChromaDex Inc. · patent 11,274,117 granted from it |
| Nov 11, 2021 | 2021/0347806 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | Organic fine chemistry | ChromaDex Inc. · patent 11,746,123 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.